FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3176673472> ?p ?o ?g. }

• W3176673472 abstract "Objective: Due to the clinical complexity of warfarin, novel oral anticoagulation (NOAC) has been a feasible and safe alternative anticoagulant approach during left atrial appendage closure (LAAC). This study was designed to compare the efficacy and safety of rivaroxaban and dabigatran for nonvalvular atrial fibrillation patients undergoing percutaneous LAAC. Methods: One single and prospective cohort study was performed among patients who received anticoagulation with dabigatran or rivaroxaban. All patients were medicated with a 3-month course of NOAC to facilitate device endothelialization, followed by dual antiplatelet therapy until 6 months, then lifelong aspirin after discharge. Repeated transesophageal echocardiography was scheduled to evaluate thrombosis formation on occluders and thrombus dissolution ability. Results: A total of 262 consecutive patients were initially enrolled. A final number of 250 patients were analyzed; two patients were excluded due to procedure failure and 10 patients had a loss of follow-up; 97 were from the dabigatran group and 153 from the rivaroxaban group. Three patients (1.9%) in the rivaroxaban group and eight (8.2%) in the dabigatran group were experiencing device-related thrombosis (DRT) events during follow-ups. Cumulative Kaplan–Meier estimates showed that the incidence of DRT was lower under rivaroxaban medication during the 6-month follow-ups ( p = 0.038*, OR = 3.843, 95%CI: 0.991–14.836). The transesophageal echocardiography (TEE) results showed that the average length and width of DRT in the rivaroxaban group was significantly lower compared with that in the dabigatran group (2.16 vs. 1.60 mm, p = 0.017*, and 1.71 vs. 1.30 mm, p = 0.003*, respectively). The thrombosis dissolved after the switch from dabigatran or rivaroxaban to warfarin within the target range, represented by the average length and width of thrombus with the cooperation of secondary TEE for the dabigatran and rivaroxaban groups (0.64 vs. 0.40 mm, p = 0.206, and 0.43 vs. 0.27 mm, p = 0.082, respectively). No significant difference was found between the two groups with respect to the levels of coagulation parameters, cardiac function, and bleeding events. Conclusion: Compared to dabigatran, post-procedural rivaroxaban anticoagulation might be advantageous in preventing DRT complications expected after LAAC, without increasing the risk of hemorrhage." @default.
• W3176673472 created "2021-07-05" @default.
• W3176673472 creator A5015907783 @default.
• W3176673472 creator A5025394309 @default.
• W3176673472 creator A5027091310 @default.
• W3176673472 creator A5048369268 @default.
• W3176673472 creator A5052523371 @default.
• W3176673472 creator A5070036406 @default.
• W3176673472 creator A5078164215 @default.
• W3176673472 creator A5086519113 @default.
• W3176673472 date "2021-06-18" @default.
• W3176673472 modified "2023-10-14" @default.
• W3176673472 title "Clinical Efficacy and Safety Comparison of Rivaroxaban and Dabigatran for Nonvalvular Atrial Fibrillation Patients Undergoing Percutaneous Left Atrial Appendage Closure Operation" @default.
• W3176673472 cites W1854704635 @default.
• W3176673472 cites W1985788916 @default.
• W3176673472 cites W2016875529 @default.
• W3176673472 cites W2115996784 @default.
• W3176673472 cites W2127884497 @default.
• W3176673472 cites W2307885737 @default.
• W3176673472 cites W2399437025 @default.
• W3176673472 cites W2523933248 @default.
• W3176673472 cites W2533525745 @default.
• W3176673472 cites W2559528249 @default.
• W3176673472 cites W2567131766 @default.
• W3176673472 cites W2620971690 @default.
• W3176673472 cites W2621231439 @default.
• W3176673472 cites W2749380187 @default.
• W3176673472 cites W2756434701 @default.
• W3176673472 cites W2762629003 @default.
• W3176673472 cites W2766540689 @default.
• W3176673472 cites W2778553000 @default.
• W3176673472 cites W2795829766 @default.
• W3176673472 cites W2802541056 @default.
• W3176673472 cites W2911614100 @default.
• W3176673472 cites W2941377816 @default.
• W3176673472 cites W2945257276 @default.
• W3176673472 cites W2948427362 @default.
• W3176673472 cites W2980816726 @default.
• W3176673472 cites W2989483265 @default.
• W3176673472 cites W2995526000 @default.
• W3176673472 cites W3043101020 @default.
• W3176673472 cites W3084230017 @default.
• W3176673472 cites W4229536675 @default.
• W3176673472 doi "https://doi.org/10.3389/fphar.2021.614762" @default.
• W3176673472 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8249758" @default.
• W3176673472 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34220493" @default.
• W3176673472 hasPublicationYear "2021" @default.
• W3176673472 type Work @default.
• W3176673472 sameAs 3176673472 @default.
• W3176673472 citedByCount "1" @default.
• W3176673472 countsByYear W31766734722022 @default.
• W3176673472 crossrefType "journal-article" @default.
• W3176673472 hasAuthorship W3176673472A5015907783 @default.
• W3176673472 hasAuthorship W3176673472A5025394309 @default.
• W3176673472 hasAuthorship W3176673472A5027091310 @default.
• W3176673472 hasAuthorship W3176673472A5048369268 @default.
• W3176673472 hasAuthorship W3176673472A5052523371 @default.
• W3176673472 hasAuthorship W3176673472A5070036406 @default.
• W3176673472 hasAuthorship W3176673472A5078164215 @default.
• W3176673472 hasAuthorship W3176673472A5086519113 @default.
• W3176673472 hasBestOaLocation W31766734721 @default.
• W3176673472 hasConcept C126322002 @default.
• W3176673472 hasConcept C141071460 @default.
• W3176673472 hasConcept C164705383 @default.
• W3176673472 hasConcept C2776301958 @default.
• W3176673472 hasConcept C2778661090 @default.
• W3176673472 hasConcept C2778810321 @default.
• W3176673472 hasConcept C2779161974 @default.
• W3176673472 hasConcept C2780813298 @default.
• W3176673472 hasConcept C2780868729 @default.
• W3176673472 hasConcept C42219234 @default.
• W3176673472 hasConcept C71924100 @default.
• W3176673472 hasConceptScore W3176673472C126322002 @default.
• W3176673472 hasConceptScore W3176673472C141071460 @default.
• W3176673472 hasConceptScore W3176673472C164705383 @default.
• W3176673472 hasConceptScore W3176673472C2776301958 @default.
• W3176673472 hasConceptScore W3176673472C2778661090 @default.
• W3176673472 hasConceptScore W3176673472C2778810321 @default.
• W3176673472 hasConceptScore W3176673472C2779161974 @default.
• W3176673472 hasConceptScore W3176673472C2780813298 @default.
• W3176673472 hasConceptScore W3176673472C2780868729 @default.
• W3176673472 hasConceptScore W3176673472C42219234 @default.
• W3176673472 hasConceptScore W3176673472C71924100 @default.
• W3176673472 hasLocation W31766734721 @default.
• W3176673472 hasLocation W31766734722 @default.
• W3176673472 hasLocation W31766734723 @default.
• W3176673472 hasOpenAccess W3176673472 @default.
• W3176673472 hasPrimaryLocation W31766734721 @default.
• W3176673472 hasRelatedWork W2049310472 @default.
• W3176673472 hasRelatedWork W2509901103 @default.
• W3176673472 hasRelatedWork W2606162097 @default.
• W3176673472 hasRelatedWork W2608094018 @default.
• W3176673472 hasRelatedWork W2609267468 @default.
• W3176673472 hasRelatedWork W2789710191 @default.
• W3176673472 hasRelatedWork W4292848028 @default.
• W3176673472 hasRelatedWork W4312065727 @default.
• W3176673472 hasRelatedWork W4322730693 @default.
• W3176673472 hasRelatedWork W1570353559 @default.
• W3176673472 hasVolume "12" @default.
• W3176673472 isParatext "false" @default.

• next